NASDAQ:VTAE (VTAE) (VTAE) Stock Price, News & Analysis → World’s biggest multibillionaire investor is buying THIS by the ton [picture] (From Stansberry Research) (Ad) Free VTAE Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Share Share Today's Range$21.00▼$21.0050-Day Range N/A52-Week Range$4.08▼$21.03VolumeN/AAverage Volume763,870 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get (VTAE) alerts: Email Address Ad Stansberry ResearchWorld’s biggest multibillionaire investor is buying THIS by the ton [picture]Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.Click here to find out what to do. About (VTAE) Stock (NASDAQ:VTAE)Vitae Pharmaceuticals, Inc. is a biotechnology company. The Company is focused on discovering and developing small molecule drugs for diseases. It is engaged in developing a portfolio of product candidates through Contour, its structure-based drug discovery platform. The Company's product candidates include VTP- 43742 for the treatment of psoriasis, as well as multiple other autoimmune disorders. The Company completed approximately two Phase I studies with VTP-43742. Its VTP-38543, a second product candidate is in a Phase IIa proof-of-concept clinical trial for the treatment of atopic dermatitis. Its VTP-36951 is for the treatment and prevention of Alzheimer's disease, or Alzheimer's. VTP-43742, the Company's wholly owned clinical candidate in an on-going Phase IIa proof-of-concept trial in psoriasis, is an orally active small molecule inhibitor of Retinoic acid-receptor (RAR)-Related Orphan Receptor gamma-t (RORgt) activity for the treatment of various autoimmune disorders.Read More Ad Stansberry ResearchWorld’s biggest multibillionaire investor is buying THIS by the ton [picture]Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.Click here to find out what to do. VTAE Stock News HeadlinesNovember 27, 2023 | msn.comMichigan, Washington move up in top five of US LBM Coaches Poll, while Ohio State tumblesJune 9, 2023 | msn.comGeorgia tax revenue falls nearly 8% in May, officials sayApril 25, 2024 | Stansberry Research (Ad)Mysterious Gold Leverage Just AnnouncedWorld's biggest multibillionaire investor group is buying THIS by the tons Most folks have completely missed the fact that there's one group of investors so powerful they're literally buying ONE THING by the tons… Stacking it in their locked vaults on pallets in record numbers.April 5, 2023 | msn.comCanada can play a big role in addressing growing food insecurity, Nutrien CEO saysFebruary 26, 2023 | msn.comTurkey rocked by another quake — the third in 2 weeksJanuary 3, 2023 | msn.com"Maybe" - Sky Sports man hints at "minutes" for Arsenal talent in FA CupDecember 21, 2022 | msn.comHow private business jet subscriptions are changing luxury travel – VistaJet and Jettly mean holidaying like a celebrity with no waiting, Michelin-star food and only 24 hours ...December 5, 2022 | msn.comClayton Kershaw signs 1-year deal to return to DodgersApril 25, 2024 | Stansberry Research (Ad)Mysterious Gold Leverage Just AnnouncedWorld's biggest multibillionaire investor group is buying THIS by the tons Most folks have completely missed the fact that there's one group of investors so powerful they're literally buying ONE THING by the tons… Stacking it in their locked vaults on pallets in record numbers.November 9, 2022 | msn.comTropical Storm Nicole Closures, Cancellations In Sarasota, BradentonSeptember 3, 2022 | thestreet.comVitae Pharmaceuticals (VTAE) Stock Skyrockets on Positive Trial ResultsAugust 10, 2022 | msn.comIndependence Island and Bailey's Island are on the market: here's a brief historyAugust 10, 2022 | msn.com‘Hell on earth’: Personal stories from UNT’s North Texas Heat Research ProjectApril 16, 2022 | nasdaq.comInteresting CIEN Put And Call Options For June 17thApril 8, 2022 | investing.comVitae Pharmaceuticals Inc (VTAE)March 10, 2022 | msn.com‘They were shooting civilians’: Ukraine refugees saw abusesJanuary 22, 2022 | thestreet.comVitae Pharmaceuticals (VTAE) Stock Downgraded on $639 Million Allergan DealAugust 27, 2021 | dailymail.co.ukAshley Graham puts her baby bump on display in bright pink bikini as she enjoys family timeAugust 19, 2021 | msn.comNorthampton County district judge, former assistant prosecutor dies after bout with cancer. ‘A voice for the voiceless’August 18, 2021 | msn.comNorthampton County district judge dies after long bout with cancerSee More Headlines Receive VTAE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for (VTAE) and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeNASDAQ SectorN/A Industry N/A Sub-IndustryN/A Current SymbolNASDAQ:VTAE CUSIPN/A CIK1157602 Webir.vitaepharma.com Phone+1-215-4612000FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report VTAE Stock Analysis - Frequently Asked Questions What other stocks do shareholders of (VTAE) own? Based on aggregate information from My MarketBeat watchlists, some companies that other (VTAE) investors own include Bausch Health Companies (BHC), Mallinckrodt (MNK), Zosano Pharma (ZSAN), Akari Therapeutics (AKTX), Aquinox Pharmaceuticals (AQXP), Sangamo Therapeutics (SGMO), Trevena (TRVN) and Arbutus Biopharma (ABUS). This page (NASDAQ:VTAE) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithHe Is Giving Away BitcoinCrypto Swap ProfitsJim Cramer’s “The Biggest Drug Ever”Behind the MarketsYour Money is Not SafeAmerican AlternativeThe AI stock to buy right nowStockEarnings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding (VTAE) Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
